3 Things You Need to Know if You Buy Moderna Today
Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...
Why Moderna Stock Jumped Over 20% This Week
As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.
Moderna: Is Stock a Buy? Breaking Down the Latest Guidance
"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...
The American Journal of Managed Care6h
Breakthrough Drugs Set to Achieve Blockbuster Status by 2030
Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.
After a Reset Year, Is Moderna Stock Poised for a Comeback?
The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...
The winter ‘quademic’? You may be sick with one of these 4 viruses
Sneezing, fever, chills, vomiting, coughing — it’s not just one virus wreaking havoc this winter; it’s a combination of four ...
Benzinga.com6d
After a Reset Year, Is Moderna Stock Poised for a Comeback?
Moderna’s mRESVIA is the first FDA-approved mRNA therapy designed to prevent respiratory syncytial virus (RSV) in adults 60 and over. The EU, Norway, Iceland, and Qatar have also approved it.
Medscape6d
RSV Vaccines Will Carry Warning for Guillain-Barré Syndrome
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
Nasdaq6d
After a Reset Year, Is Moderna Stock Poised for a Comeback?
Moderna CEO Stephane Bancel commented, "In 2024, we achieved $3.0 - 3.1 billion in product sales, approval of our RSV vaccine and continued to adapt our COVID-19 business for the endemic setting.